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Abstract 
Background  
 Predictor analyses of late-life depression can be used to identify variables associated with 
outcomes of treatments, and hence ways of tailoring specific treatments to patients. The aim of this 
review was to systematically identify, review and meta-analyse predictors of outcomes of any type 
of treatment for late-life depression. 
Methods 
 Pubmed, Embase, CINAHL, Web of Science and PsycINFO were searched for studies 
published up to December 2016. Primary and secondary studies reported treatment predictors from 
randomised controlled trials of any treatment for patients with major depressive disorder aged over 
60 were included. Treatment outcomes included response, remission and change in depression 
score. 
Results 
Sixty-seven studies met the inclusion criteria. Of 65 identified statistically significant predictors, only 
7 were reported in at least 3 studies. Of these, 5 were included in meta-analyses, and only 3 were 
statistically significant. Most studies were rated as being of moderate to strong quality and satisfied 
key quality criteria for predictor analyses. 
Limitations 
The searches were limited to randomised controlled trials and most of the included studies were 
secondary analyses. 
Conclusions 
Baseline depression severity, co-morbid anxiety, executive dysfunction, current episode duration, 
early improvement, physical illnesses and age were reported as statistically significant predictors of 
treatment outcomes. Only the first three were significant in meta-analyses. Subgroup analyses 
showed differences in predictor effect between biological and psychosocial treatment. However, 
high heterogeneity and small study numbers suggest a cautious interpretation of results. These 
predictors were associated with various mechanisms including brain pathophysiology, perceived 
social support and proposed distinct types of depressive disorder. Further investigation of the 
clinical utility of these predictors is suggested. 
 
Keywords: Systematic review, meta-analysis, predictor, late-life depression, major depressive 
disorder. 
 
 
Introduction 
Depression in late-life is one of the most prevalent and disabling disorders for the elderly. Although, 
various pharmacologic and psychosocial treatments are available, a significant portion of patients 
with late-life depression remain symptomatic or have a delayed recovery (Roose and Schatzberg, 
2005). Differentiating those who are likely to have a good or poor response to treatment may have 
useful clinical applications: i) to inform patients about prognosis; ii) to speed up treatment 
adjustment; and iii) to tailor appropriate treatments to specific patients. A predictor is a variable or 
set of variables that can determine the possible outcome of an intervention in a population 
(Nierenberg, 2003). Predictors can be identified from demographic data, clinical characteristics, and 
routine and specific investigation results.  
There are only a limited number of reviews of predictors of treatment outcome in late-life 
depression. Alexopoulos et al. (1989) reviewed the literature, and argued that the results of 
predictor studies which had used mixed-age populations might not be applicable to geriatric 
populations. They suggested that comorbid medical illness, duration of depressive episode, 
dysthymia and “double depression” (dysthymia in addition to major depression), personality 
disorder and neuroimaging abnormality predicted chronicity of a depressive episode in older adults. 
In a meta-analysis of RCTs of cognitive behavioural therapy, Gould et al. (2012) found that 
treatment-related, study design and quality-related factors (such as concurrent pharmacotherapy, 
use of an active or non-active control, type of outcome measure and selective outcome reporting), 
but not demographic or clinical variables, were associated with the magnitude of treatment 
outcome. In a patient-level meta-analysis, Nelson et al. (2013) reported three predictors that 
moderated drug- placebo differences from 10 RCTs of second-generation antidepressants in late-life 
depression; increased age, illness duration from first onset and depression severity. In their meta-
regression of 34 RCTs of antidepressants in older people with major depression, Calati et al. (2013) 
showed that male sex, increasing age, being Caucasian, less severe baseline depression and longer 
duration of episode had negative effects on the outcome of antidepressant treatment. Pimontel et 
al. (2016) found in their meta-analysis that impairments in executive functioning, specifically 
planning and organisation, were associated with poorer immediate antidepressant treatment 
response. Aizenstein et al. (2014) showed in their review that brain volume loss, lower white matter 
integrity and alteration of activity seen in fMRI in certain regions were associated with poorer 
treatment outcomes. Further, De Crescenzo et al. (2016) found in their systematic review that FDG-
PET imaging may predict treatment response to antidepressants by showing reduced glucose uptake 
in several brain areas. 
To the authors' knowledge, no recent systematic review and meta-analysis has examined predictors 
of treatment outcome in a broad range of treatments for late-life depression (including 
pharmacological, psychological, psychosocial and care management interventions). A previous 
comprehensive review of treatments was conducted in 1989 and is clearly in need of updating given 
the number of studies that have been published since then (Alexopoulos et al., 1989). The aim of this 
systematic review was to identify and critically appraise predictors of treatment outcome in RCTs of 
any intervention in comparison to active or non-active control conditions (e.g. placebo or treatment 
as usual) for late-life depressive disorder. The aim of the meta-analysis was to calculate the 
aggregated effect size of consistently reported predictors. Outcomes of interest included treatment 
response, remission or change in score on standardised depression questionnaires. 
 
Method 
 
Identification of studies 
Online bibliographic databases (Pubmed, Embase, CINAHL, PsychINFO and Web of Science - all years) 
were searched on 6 December 2016. References of published reviews and studies were also 
manually searched. . The following terms were used to search the databases: 
(depress*) AND (“older adult” OR “old age” OR elder* OR geriatr* OR “late onset” OR late-onset OR 
“late life” OR late-life) AND (random* OR RCT OR “clinical trial” OR “control* trial*”) AND (predict* 
OR moderat* OR mediat* OR regress*) 
Titles and study abstracts were initially screened by CT in order to determine eligibility for retrieval. 
Retrieved articles were then screened for eligibility and selected for inclusion using a structured 
proforma. Studies were independently and blindly screened and selected by CT and co-authors 
(RLGa, HG, MC, EW, GR, TS or AT), and disagreements were resolved through discussion. Unresolved 
discrepancies were discussed with RLG. 
 Inclusion/exclusion criteria 
Studies were included if they met the following criteria: 
1. Peer-reviewed RCT or secondary analysis of data from a peer-reviewed RCT; 
2. Any intervention (e.g. pharmacological, psychological, psychosocial or care management); 
3. Non-active (e.g. treatment as usual) or active control condition (e.g. placebo), or other 
comparative treatment condition; 
4. Sample size was greater than 5 in each condition; 
5. Participants were aged 60 or more (studies including older and younger participants were 
included only if separate analyses were conducted for older participants); 
6. Participants had diagnosis of major depression according to DSM/ICD criteria or established 
criteria; 
7. Reported statistical significant data on predictors, moderators or mediators of treatment 
outcome, specifically, treatment response, remission and/or change in the score on 
standardised depression questionnaires; 
8. In English language. 
 
Assessment of study quality 
The Quality Assessment Tool for quantitative studies from the Effective Public Health Practice 
Project (EPHPP) (Thomas et al., 2004) was used to assess study quality.  In addition, critical appraisal 
criteria were developed in order to assess the quality of predictor analyses (and hence findings), 
based on a systematic review by Knopp et al. (Knopp et al., 2013; Pincus et al., 2011; Sun et al., 
2012) . These criteria were: 
1. Whether the predictors were assessed by a validated assessment tool as the validity and 
reliability of the assessment tools will ensure the accuracy of the predictors; 
2. Whether the predictors were measured before randomisation or delivery of the intended 
intervention as some baseline factors may change after the allocation or be changed by the 
awareness of allocation; 
3. The number of tested predictors was less than 5 as the fewer factors analysed, the greater 
reliability and credibility to accept or reject the predictors; 
4. Whether there was a hypothesis in relation to the predictors as the selection of analysed 
factors should be based on theory or evidence in order to confirm meaningful predictors; 
5. Whether there was an analysis of interactions between predictors and treatment arms as 
this may reveal underlying moderator effects. 
Studies were independently and blindly rated by CT and co-authors (RLGa, HG, MC, EW, GR, TS or 
AT), and disagreements were resolved through discussion. Unresolved discrepancies were discussed 
with RLGo. 
Data extraction 
Data on a range of clinical and research characteristics were extracted using a structured proforma. 
Data were extracted independently and blindly by CT and co-authors (RLGa, HG, MC, EW, GR, TS or 
AT), and disagreements were resolved through discussion. Unresolved discrepancies were discussed 
with RLGo. Original studies were also retrieved and data extracted if studies of secondary data 
analyses provided insufficient information. 
 
Meta-Analysis 
Effect size 
Predictors included in the meta-analysis were reported by at least 3 studies from the systematic 
review. For each study, odds ratios or information that could be used to calculate odds ratios were 
independently extracted by two authors (CT and KK). Any disagreements were resolved through 
discussion. Studies were excluded from the meta-analysis if insufficient data were reported to 
calculate odds ratio effect sizes. The effect size of interest was the overall effect size that included 
information from both treatment and comparison arms to reflect a difference in outcome for each 
predictor. Odds ratios were selected as the effect size of choice for this review for two reasons: i) it 
was the most frequently reported effect size in the included studies (18 out of 36 studies); and ii) 
conversion of odds ratios into other effect sizes tends to result in over- or under-estimation of effect 
sizes (Lipsey and Wilson, 2001). Odds ratios were obtained through direct extraction from included 
studies, calculations from factorial tables or conversions from other reported effect sizes. Results 
from studies that only reported statistical outcomes were converted into standardised mean 
differences using an effect size calculator (Wilson, 2001), and then converted to odds ratio using 
Hasselblad and Hedges’ method (Hasselblad and Hedges, 1995). This has been shown to be the most 
robust method for this type of effect size conversion (da Costa et al., 2012) .  
Statistical analysis 
Only predictors that were reported in 3 or more different studies were included in the meta-analysis. 
If studies reported more than one type of outcome measure for the same predictor, only one 
outcome was extracted. These were prioritised in the following order; remission, response (i.e. 
percentage reduction in score) and score or categorical outcome (e.g. high persistent, high decline 
and low decline). Remission was prioritised because it often reflects the use of more rigorous criteria 
and longer term improvement of symptoms than response, or changes in score or category of 
severity.  
Separate meta-analyses were conducted for predictor variables that were reported in at least 3 
different studies. Odds ratios were log-transformed for input into meta-analyses and back-
transformed for reporting purposes. Random-effect models were used to aggregate the effect sizes 
(DerSimonian and Laird, 1986). Statistical significance of the estimated overall odds ratio in each 
meta-analysis was examined using the Z test. Cochran’s Q-test of heterogeneity and I
2
 statistic were 
calculated to examine between-study variability due to heterogeneity rather than sampling error or 
chance. Values of 0, 25, 50 and 75% indicated no, low, moderate and high heterogeneity 
respectively (Higgins et al., 2003). Publication bias was estimated using Egger’s regression 
asymmetry test, which is suitable for small numbers of studies (Egger et al., 1997). If publication bias 
was detected, a nonparametric trim-and-fill method was used to impute missing studies and re-
estimate the pooled effect size (Duval and Tweedie, 2000) . An alpha level of 0.05 was used for tests 
of the estimated overall odds ratio and publication bias, while 0.10 was used for tests of 
heterogeneity due to reductions in sensitivity of Cochran's Q test with small numbers of studies. 
Using the same procedures as above, subgroup analyses were performed in order to examine 
whether any between-study heterogeneity could be explained by type of treatment. Differences in 
overall effect sizes between subgroups were assessed using a test of heterogeneity. Bonferroni-
corrections were applied to alpha levels in order to control for the risk of false positives across 
multiple subgroup analyses. Data were analysed using Stata 14.0 (StataCorp, College Station, TX). 
 
Results 
As shown in the PRISMA flow diagram (Figure 1), 6,706 articles were identified through database 
searches and 19 additional articles were identified from manual searches of related reviews. After 
removing duplicates, 4,869 articles were initially screened. The full-texts for 207 articles were 
retrieved and further screened for eligibility. 67 articles were selected after screening. 
Demographic and clinical characteristics 
Demographic and clinical characteristics were variable across studies, and some data could not be 
extracted for several studies (Table 1). About half of the studies included 100-500 participants, with 
7 studies including more than 500 and 3 studies including more than 1000. The majority of studies 
included participants with a mean age greater than 70 (38/67), who were female and of white 
ethnicity. The Mini-Mental State Examination, a brief cognitive screening tool, was used to screen 
for dementia in most of the studies (49/67). Most of the included studies used the Hamilton 
Depression scale in recruitment and monitoring the participants (63/67), and the majority included 
participants with moderate to severe depression (25/67 with 15 not available).  
Study characteristics 
Eligible studies shared considerable similarities with respect to study characteristics (see Table 2). 
Studies were published from 1994 to 2016. Most of the studies used DSM-related diagnostic criteria, 
only 4 used other diagnostic systems. Treatment in the majority of studies comprised antidepressant 
medications (38/67); in addition, 19 studies involved a care management intervention and 15 studies 
investigated psychological treatments. Further, 37 studies utilised placebo or treatment-as-usual as 
control conditions; 30 studies used different antidepressants, biological or psychosocial 
interventions as comparator conditions. Most of the included studies involved secondary data 
analyses (45/67); only 22 examined predictors in their primary analyses. 40 studies had a duration of 
follow-up of 12 weeks or less, and only 12 studies monitored participants for at least 1 year. 
Quality assessment 
As shown in Table 3, the components of the quality assessment tool that were most adequately 
addressed were study design, data collection methods, confounders and selection bias. The least 
adequately addressed component was intervention integrity. All studies received a strong rating for 
study design as only RCTs were included in the review. 98.5%, 95.5%, 88.1% and 83.6% of studies 
had a moderate to strong rating for data collection methods, analysis, confounders and blinding, 
respectively. In contrast, 71.6% of studies had a moderate to strong rating for selection bias, and 
withdrawal and drop-outs. Furthermore, the majority of studies (68.7%) received a weak rating for 
intervention integrity, which involved assessing whether participants receiving the allocated 
intervention, measurement of intervention consistency and intervention contamination control. 
Critical appraisal of the quality of predictor analyses showed that most studies generally reported 
satisfactory analyses (see Table A in the Appendix). 97.0% of studies used validated assessment tools 
to assess predictors. 76.1% had measured predictors before randomisation or receiving intervention. 
56.7% had analysed less than 5 predictors and 70.2% had an a priori hypothesis in relation to the 
predictors. However, only 46.3% of studies tested for an interaction between predictors and 
treatment type.  
Predictors of treatment outcome 
Statistically significant predictors of treatment outcomes (with respect to treatment response, 
remission and/or change in depression scores) are reported in Table 3. Although 65 different 
statistically significant predictors were identified, only 7 were reported by at least 3 studies. These 
predictors were age, baseline depression severity, early improvement, current episode duration, 
baseline anxiety symptoms, physical illness and set shifting in the trail making test. Nine predictors 
were reported by two studies, and 49 predictors were reported by only one study. 
The types of treatment that were examined in the studies that reported these 7 predictors are 
illustrated in Figure 2. The same type of relationship between treatment outcome and the predictor 
variable (i.e. positive or negative) was reported for all predictors, with the exception of age and 
baseline depression. 
Meta analyses 
Only five out of the seven above predictors were submitted to meta-analyses due to insufficient data 
to calculate effect sizes for two predictors (early improvement and current episode duration). Out of 
the five predictors submitted to meta-analyses, baseline anxiety, baseline depression and the trail 
making test were the only predictors that remained statistically significant after effect size 
aggregation (see Table 4). Physical illness showed a marginal significant effect in the meta-analysis. 
However, high levels of heterogeneity were found in all meta-analyses, with the exception of the 
trail making test. Furthermore, a statistically significant publication bias was found in the meta-
analysis of baseline anxiety, baseline depression and physical illness. However, the pooled effect size 
remained unchanged after adjusting for publication bias using a trim-and-fill method. 
Subgroup analyses 
Predictor variables submitted to meta-analyses were additionally submitted to subgroup analyses 
organised by treatment type (biological vs. psychosocial vs. biological plus psychosocial). The 
biological sub-group consisted of pharmacological treatment and rTMS/ECT trials, the psychosocial 
group comprised psychological treatment trials, and the biological plus psychosocial group consisted 
of care management and combined treatment trials. After correcting for multiple comparisons, 
significant differences were found in subgroup analyses comparing type of treatment for age, 
baseline depression, baseline anxiety and physical illness, but not executive functioning (Table 5). 
Pooled effect sizes were mostly small to moderate in magnitude, with a considerable degree of 
within-group heterogeneity.  
Discussion 
Of the 65 statistically significant predictors identified from 67 studies of RCTs, only 7 were reported 
in at least 3 studies and only 5 of these provided sufficient information to permit a quantitative 
evaluation of effect sizes in meta-analyses. These will now be addressed in turn: 
 
Age 
Older age, as a predictor of treatment outcome, is controversial in our findings. Of the 6 studies 
reporting this variable, 4 reported a negative predictor relationship between age and outcome (the 
older the age, the poorer the outcome), while two studies reported a positive relationship. The 
study that reported a positive relationship showed a greater speed of response with older age but 
not overall response rate. Although, it would generally appear that older age is a negative predictor 
of good treatment outcome, which corresponds with previous meta-regression analyses (Calati et 
al., 2013), our meta-analysis failed to show a statistically significant pooled effect size. A high level of 
heterogeneity may have been caused by variations in treatment modalities (e.g. pharmacotherapy, 
psychotherapy and care management) and outcome definitions. The subgroup analysis showed that 
older age had a small to moderate significant effect on the outcome, but only in biological treatment 
trials. Studies have suggested that age-related brain changes may lower the response to 
interventions through various mechanisms. For example, Meltzer et al. (2001) demonstrated that 
serotonin-1A receptor density was decreased in healthy older adults compared with healthy younger 
adults, which may slow or reduce the effect of drugs targeting serotonin transmission. Nahas et al. 
(2004) also reported that frontal lobe atrophy with advancing age reduced the effect of rTMS 
treatment. Further, Ribeiz et al. (2013) found that reduced gray matter volume in the orbitofrontal 
cortex was associated with poorer antidepressant response in elderly patients, which suggests that 
treatment response may partly depend on the integrity of emotional regulation. In conclusion, older 
age may be a negative predictor of treatment outcome, especially in biological treatment trials, 
which can be explained by established age-related brain changes such as brain atrophy and 
serotonin receptor density reduction. 
 
Baseline depression severity 
Baseline depression severity was the most frequently reported statistically significant predictor in 
our systematic review, despite some inconsistencies among the studies. It was reported in 16 studies 
which used two different methods to identify predictors; the first involved examining overall 
treatment outcome, and the second focused on the effect of the intervention in order to delineate 
the drug-placebo difference. 
When examining overall treatment outcome, 13 out of 16 studies reported a negative prediction 
relationship between baseline depression severity and treatment outcomes (the higher the baseline 
severity, the poorer the outcome). In addition, most of the studies reported this for remission.  
Several possibilities have been suggested to explain this association. First, Ackerman et al. (1997) 
commented that it is easier to reach an endpoint if you start with a lower baseline score of 
depression. Second, Nasser and Overholser (2005) observed that perceived social and emotional 
supports were associated with reduction of depression, and more severe depression might reduce 
access to these perceived supports, which may further diminish treatment response. Third, more 
permanent or severe underlying pathology may underlie more severe baseline depression, which 
may lessen the effect of treatment.  
For analyses that focused on the drug-placebo difference, only 3 studies reported a positive 
direction for response and depression score, but not remission. Patients with a higher baseline 
depression severity demonstrated more of an antidepressant effect compared to placebo. This 
association has been suggested to be due to those with higher baseline severity having greater room 
for improvement than those with lower baseline severity (Kirsch et al., 2008; Roose et al., 2004a).  
A meta-analysis of 14 studies showed a small, but statistically significant overall effect size in 
negative direction for this predictor. However, high levels of heterogeneity were also found and 
therefore caution must be expressed when interpreting these results. The subgroup analysis showed 
that baseline depression was significantly associated with poorer outcome, but only in biological plus 
psychosocial treatment trials. However, the analysis also showed high levels of within-group 
heterogeneity. Our findings were different from other meta-analysis studies because we looked at 
the predictor’s effect on overall outcome, whereas others focused on the predictor’s effect on the 
differences between intervention and comparison groups. Locher et al. (2015) did not find a 
relationship between baseline severity and change in symptoms in either antidepressant or placebo 
group in their meta-analysis. However, the study did not consider treatment duration in their 
analysis and limit to antidepressant studies, which may have produced the non-significant result. By 
contrast, two meta-analysis studies (Khan et al., 2005) showed that more severe baseline depression 
was associated with a higher response rate to treatment, and therefore larger treatment effect in 
patients who had a longer illness duration. Calati et al. (2013) suggested that a higher baseline 
depression group may have a better chance to reach the proportional reduction threshold than a 
lower baseline group. In conclusion, we found that higher baseline depression severity may be 
associated with poorer outcome in overall treatment. However, previous meta-analysis studies 
indicated that higher baseline depression may relate to more pronounced intervention effects than 
lower severity, though the reasons for this are unclear. 
 
Early improvement 
Early improvement was reported in 3 studies as a positive predictor of treatment outcomes. The 
range of what was considered as the early improvement period was from 1 week to 3 weeks. 
However, Volz et al. (1995) suggested that the predictive value of early improvement on treatment 
outcome may be small. Rodin and Voshart (1986) noted that an abrupt and transient improvement 
was associated with placebo response; however, gradual and persistence improvement was 
associated with antidepressant treatment. Donovan et al. (1994) also observed that a significant 
portion of patients who did not respond to antidepressant in 4 weeks finally improved after 6 weeks 
of treatment which indicated low specificity of prediction. Thus, although early improvement was 
statistically identified as a predictor, its clinical value may be limited. It was not possible to submit 
this predictor to meta-analysis due to insufficient data. 
 
Current episode duration 
Current depressive episode duration was reported in 3 studies as a negative predictor; with longer 
episodes being associated with poorer outcome. This predictor has been reported in several studies, 
but the explanation was limited (Alexopoulos et al., 1989; Calati et al., 2013; Goodkind et al., 2016; 
Moller et al., 2010; Pimontel et al., 2012). Keller et al. (1986) suggested that episode duration was an 
intrinsic feature of each individual patient. As for baseline severity, a more permanent, chronic 
condition or severe underlying pathology may underlie a longer duration, which may lessen the 
effect of treatment and hence be associated with poorer response. Again, a meta-analysis was not 
conducted for this predictor due to insufficient data. 
 
Baseline anxiety symptoms 
Baseline anxiety symptoms were consistently reported in 7 studies as a negative predictor of 
treatment outcome. Furthermore, one additional study reported symptoms of worry and panic as a 
negative predictor too. A meta-analysis of 7 studies showed a statistically significant small to 
moderate negative overall effect size for this predictor. However, high levels of heterogeneity and 
statistically significant publication bias were also found and therefore caution must be expressed 
when interpreting these results. In the subgroup analysis, baseline anxiety was significantly 
associated with poorer outcome in biological treatment trials, but not biological plus psychosocial 
treatment trials. This finding is consistent with other reviews (Goodkind et al., 2016; Moller et al., 
2010; Pimontel et al., 2012). Although, Nelson et al. (2009) reported that anxiety symptoms were 
not associated with the effect of antidepressant when compared to placebo, patients with comorbid 
anxiety symptoms had lower remission rates than the non-anxious group. Although overlapping 
genetic and neurobiological factors of depression and anxiety have been reported in previous 
studies (Morimoto et al., 2012; Morimoto et al., 2011), more recent brain imaging studies have 
showed more distinct features between depression alone and depression with anxiety symptoms. 
For example, Canu et al. (2015) revealed that patients with depression and anxiety may have more 
severe cortical atrophy in areas that correspond with anxiety symptoms than patients with 
depression alone. Potvin et al. (2015)  suggested that anxiety may be associated with smaller cortical 
thickness in the elderly. Furthermore, Domschke et al. (2010) found that the neuropeptide Y gene, 
which was found in anxious depressed patients, affected antidepressant treatment response, and 
Baffa et al. (2010) observed that serotonin gene variation influenced antidepressant treatment 
response in this group of patients. Based on these distinct clinical pictures and biological evidence, 
Ionescu et al. (2013) suggested a differentiation between anxious depression and non-anxious 
depression. Late-life depression patients with anxiety symptoms may have more severe brain 
pathology or genetic vulnerabilities that reduce the effect of treatment. Co-morbid anxiety 
symptoms were associated with poorer outcome and may be an important sign that the patient 
needs additional treatment or will have a longer time to remission.  
 Physical illness 
Physical illness (e.g. overall comorbidity diseases and chronic illnesses such as hypertension, 
diabetes, cancer and renal disease) were consistently reported as a negative predictor in 6 studies. 
In addition, 5 studies reported pain, cerebrovascular disease, limitation of physical function and 
dyspnoea-related disability to be negative predictors of treatment outcomes. By contrast, one study 
reported that headache before receiving treatment was related to better treatment response. A 
meta-analysis showed a very small and marginal statistically significant pooled effect size, in 
conjunction with a high level of heterogeneity. Although the subgroup analyses showed a significant 
difference between treatment types, this result should be interpreted with caution given that 4 out 
of 5 studies were biological plus psychosocial treatment trials. Physical illness may complicate 
depressive outcome through both biological and psychological pathways. Illnesses that directly 
affect the brain may interrupt neurotransmitter and neural network pathways, and non-neurological 
illness may indirectly affect the brain via inflammatory process and HPA axis regulation (Brown et al., 
2004; Marson et al., 1997). Furthermore, illnesses that result in disability and pain may induce 
additional psychological stressors such as lowered self-esteem, dependency, prolonged discomfort 
and loss of social relationships (Rackley and Bostwick, 2012; Rodin and Voshart, 1986). In addition, 
depression may affect the course and incident of medical illnesses such as cardiovascular diseases, 
neurological diseases, diabetes and HIV (Marson et al., 1997). Thus, physical illness may be a 
predictor of treatment outcome that not only influences depression prognosis but also is affected by 
depression. 
 
Executive functioning 
Performance on the Trail Making Test, particularly the ability to perform the set shifting task, was 
consistently shown to positively predict depression outcomes in 3 recent studies. In addition, the 
meta-analysis showed a moderate statistically significant effect size, with no evidence of 
heterogeneity or publication bias. No significant difference was found between treatment types in 
subgroup analyses for this predictor. However, this finding was contradicted in a recent cohort study 
in which the Trail Making Test was not associated with likelihood of remission (Clery-Melin and 
Gorwood, 2017). This contradiction may be explained by the fact that the cohort study was done in 
adult population and low number of participants who completed the predictor assessment (25%).  In 
addition, performance on other executive functioning tests might predict treatment outcome. Two 
studies showed that impairment in response inhibition in the Stroop test was related to worse 
outcome, and another study reported that higher scores on a coding task and processing speed were 
related to better outcome. This result is not supported by a recent meta-analysis which showed that 
only performance on planning and organisation tasks was related to treatment response (Pimontel 
et al., 2016). However, this meta-analysis only included studies of acute (6- 12 weeks, mean 9.75 
weeks) treatment outcome of antidepressants, whereas the current review included studies with 
much longer treatment durations (8-96 weeks, mean 26.00 weeks ) in various treatment conditions. 
Another meta-analysis review showed that only the Initiation-Perseveration subscale of the Mattis 
Dementia Rating scale, a verbal fluency test, was associated with antidepressant response 
(McLennan and Mathias, 2010). A cohort study showed that Wisconsin Card Sorting Test, but not 
verbal fluency or Stroop test, was associated with response to cognitive behavioural treatment 
(Goodkind et al., 2016). These inconsistencies in evidence in older patients may lead to the 
explanation that different executive function tasks specifically predict different treatment 
conditions.  
Changes in frontal brain regions and neural networks may underlie the relationship between 
executive functioning and treatment outcome in late-life depression. For example, Alexopoulos et al. 
observed that patients with late-life depression who had impairment in executive functioning had 
poorer depression outcome (Alexopoulos et al., 2005b; Alexopoulos et al., 2002). Furthermore, the 
impairment was linked to lower frontal subcortical and limbic volume. Patel et al. (2015) reported 
that patients with late-life depression who had lower functional connectivity in the dorsal default 
mode network had better treatment outcome. Karim et al. (2016) reported differences in brain 
activity in frontal and temporal cortices involving the anterior salience network and default mode 
network between remitted and non-remitted late-life depression patients. Therefore, intact 
executive function may indicate less severe pathology or preserved ability to respond to treatment. 
 
 
Clinical and research implications 
Predicting treatment outcome in late-life depression may aid clinicians in three ways: i) it may serve 
as a useful guide to seek out information that can be used to inform and influence clinical decisions; 
ii) it may aid better decision making (e.g. whether to switch or augment treatment); and iii) it may 
better inform patients about the possible prognosis. Identifying patients with good and poor 
outcomes with these predictors may lead to better understanding of the nature of late-life 
depression and new treatment options. However, current data on each predictor is still scarce. 
Further evidence of the validity and effect of these predictors is required, in addition to replications 
of these data. Further investigation of how predictors may be integrated into clinical practice to aid 
decision making is essential for the development of new treatments that could improve 
effectiveness for patients with poorer outcomes. 
 
Strengths and limitations 
The main advantage of this systematic review is the broad range of interventions for late-life 
depression that were considered, thus providing a comprehensive summation of the literature. The 
benefit of using data from RCTs is the low rate of data attrition that can cause observational bias in 
other types of studies. 
However, there were a few limitations in this systematic review. Studies that were included were 
limited to data from peer-reviewed RCTs, rather than from grey literature such as clinical trials 
databases. Thus, this review may be subject to publication bias. A wider search including grey 
literature may have identified additional relevant studies to include in the review, although this may 
have introduced further bias as unpublished studies may be of lower methodological quality (Egger 
et al., 2003). Furthermore, 67% of included studies were secondary analyses, which questions the 
statistical validity of the predictors that we have identified. For example, secondary analyses may 
have failed to detect statistically significant predictor variables simply due to being underpowered 
for these analyses. The analysis methods employed by different studies also varied, and so caution 
should be applied when interpreting the validity of the predictors as a group. However, the fact that 
the majority of studies used regression analysis may lessen this concern. 
There were also a few limitations in the meta-analysis. A selection bias may have been introduced as 
studies were only included if they reported statistically significant predictors. Furthermore, small 
number of studies reported for each predictor variable, coupled with a variety of treatment 
modalities introduced high levels of heterogeneity. Therefore, although the results of the meta-
analyses may be of clinical value, they should be interpreted with caution. Subgroup analyses 
examined whether any between-study heterogeneity in effect sizes could be explained by the type 
of treatment. However, these analyses were limited by small numbers of studies and considerable 
heterogeneity within at least one subgroup for each predictor. Furthermore, although significant 
subgroup differences were found for these predictors, the possibility that a moderating variable 
other than treatment type may have been responsible for these differences cannot be ruled out. 
 
Conclusions 
In this systematic review, we found that older age, higher baseline depression severity, slower 
improvement, longer current episode duration, higher co-morbid baseline anxiety symptoms, the 
presence of physical illness and impairment of executive functioning are predictors of poor 
treatment outcomes. Of these seven predictor variables identified in 3 or more studies, meta-
analyses confirmed that baseline depression, baseline anxiety, physical illness and executive function 
and were significantly associated with treatment outcome. Subgroup analyses found differences in 
predictor effect between biological treatment trials, psychosocial treatment trials and biological plus 
psychosocial treatment trials. Other statistically significant predictors were identified from eligible 
studies, but there were very few replications of these predictors. These results come from post-hoc 
analyses of RCT data which may question the validity of these conclusions.  
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Figure 2: Bar chart of predictors reported in 3 or more studies, stratified by treatment type. 
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Figure 3: Forest plot of each predictors included in the meta-analysis 
 
 
 
Table 1: Demographic and clinical characteristics 
Age
Baseline depression
Early improvement
Current episode duration
Baseline anxiety
Physical illnesses
Trail making test
Negative 
pharmacologic psychotherapy care management rTMS / ECT combined
pharmacologic psychotherapy care management rTMS / ECT combined
Positiv
14 12 10 8 6 4 2 0 2
Study 
year 
count
ry 
Old 
age 
samp
le 
size 
M
ea
n 
ag
e 
Mean 
years 
of 
educat
ion 
% 
women 
% 
whit
e 
ethn
icity 
Scr
ee
ni
ng 
to
ol 
an
d 
m
ea
n 
co
gni
tiv
e 
sc
or
e 
De
pr
ess
ion 
Ra
tin
g 
sca
le 
na
me 
De
pr
ess
ion 
Ra
tin
g 
sca
le 
cri
ter
ia  
for 
EN
TR
Y 
Mean 
depressiv
e severity 
at ENTRY 
Mea
n age 
of 
onse
t 
duration 
of illness 
at enter 
(wk) 
Ackerm
an 
1997 
US 
671 N/
A 
N/A N/A N/A M
M
SE 
(N
/A) 
HA
M
D1
7 
16 N/A N/A N/A 
Ackerm
an 
2000 
US 
671 N/
A 
N/A N/A N/A M
M
SE 
(N
/A) 
HA
M
D1
7 
16 N/A N/A N/A 
Adeoye 
2000  
US 
15 69
.2 
N/A 53.33 93.3
3 
N/
A 
HA
M
D 
15 19.06 N/A N/A 
Alexopo
ulos 
2005 
US 
215 N/
A 
12.79 71.57 67.5
5 
M
M
SE 
(2
7.3
5) 
HA
M
D 
18 18.8 N/A N/A 
Alexopo
ulos 
2014 
US 
138 70
.9
5 
13.37 65.94 N/A M
M
SE 
(2
7.4
) 
HA
M
D1
7 
14 19.05 N/A N/A 
Alpert 
2003  
US 
22 67
.2
8 
N/A N/A N/A N/
A 
HA
M
D2
4 
18 24.3 N/A N/A 
Andrees
cu 
2007 
US 
170 76
.6
8 
12.95 64.75 92.0
4 
M
M
SE 
(N
HA
M
D1
7 
15 20.64 61.9
4 
109.38 
/A) 
Andrees
cu 
2009 
US 
166 76
.6
3 
13.03 65.06 92.7
7 
M
M
SE 
(N
/A) 
HA
M
D1
7 
15 core item 
subscale 
7.08 
61.8
5 
109.63 
Azar 
2011 
US 
792 73
.6
3 
* 32.45 37.2
5 
N/
A 
CE
S-
D 
N/
A 
28.31 N/A N/A 
Banerje
e 
1996  
UK 
69 80
.7
1 
N/A 82.61 N/A N/
A 
M
AD
RS 
N/
A 
26.25 N/A N/A 
Bao 
2011  
US 
396 * * 70.89 65.1
7 
M
M
SE 
(N
/A) 
CE
S-
D 
20 20.54 N/A N/A 
Beaudre
au 
2015 
US 
46 70
.7
8 
15.78 65.2 69.6 M
M
SE 
(N
/A) 
HA
M
D 
20 22.54 N/A N/A 
Bjolseth 
2015 
Norw
ay 
73 74
.8
1 
N/A 53.42 N/A M
M
SE 
(2
7.5
9) 
HA
M
D1
7 
18 24.72 N/A 28.4 
Bogner 
2007  
US 
599 70
.3 
12.8 71.6 70.2 M
M
SE 
(2
7.4
) 
HA
M
D2
4 
N/
A 
17.28 N/A N/A 
Bogner 
2012  
US 
599 70
.2 
12.8 72% 70.2 M
M
SE 
(2
7.4
) 
HA
M
D2
4 
10 N/A N/A N/A 
Bondar
eff 
2000 
US 
210 67
.8
5 
* 59.04 93.8
1 
M
M
SE 
(N
/A) 
HA
M
D2
4 
18 24.75 48.6
5 
156
†
 
Cappeli
ez 
2007 
Cana
da 
68 N/
A 
* 67 N/A Ph
ysi
cia
n's 
cli
SC
L-
20 
N/
A 
1.675 N/A N/A 
nic
al 
ju
dg
m
en
t 
(N
/A) 
Chan 
2013 
Singa
pore 
26 69
.7 
* 80.8 0 N/
A 
GD
S-
15 
4 7.16 N/A N/A 
Chan 
2014 
Singa
pore 
29 * * 79.3 0 N/
A 
GD
S-
15 
4 5.47 N/A N/A 
Coon 
2003  
US 
58 66
.6 
14.6 68.25 N/A M
M
SE 
(N
/A) 
HA
M
D 
15 N/A N/A N/A 
Evans 
1997
b  
UK 
82 80
.4 
N/A 75.61 N/A M
M
SE 
(*) 
HA
M
D1
7 
N/
A 
20.75 N/A N/A 
Eyre 
2016 
US 
35 69
.1
8 
15.12 56.94 N/A M
M
SE 
(2
8.3
9) 
HA
M
D2
4 
16 18.86 40.1
7 
N/A 
Fields 
2012  
US 
449 75
.1 
* 46.5 94.2 3-
M
S 
(9
4) 
GD
S 
6 8.7 N/A N/A 
Gasto 
2003  
Spain 
68 70
.8
3 
N/A 63.24 N/A M
M
SE 
(N
/A) 
HA
M
D1
7 
21 26.52 N/A N/A 
Ghesqui
ere 
2014 
US 
417 70
.0
2 
12.86 71.46 70.0
5 
M
M
SE 
(N
/A) 
CE
S-
D 
20 17.95 N/A 202.24
†
 
Gildeng
ers 
2002 
US 
323 70
.3 
12.3 72.8 91.3 M
M
SE 
(2
HA
M
D1
7 
15 22.1 N/A 22 
8.1
) 
Gilman 
2013  
US 
1226 * * 70 69.5 M
M
SE 
(N
/A) 
CE
S-
D 
20 11.4 N/A N/A 
Greenle
e 
2010  
US 
124 72
.2
9 
N/A 68.35 N/A M
M
SE 
(N
/A) 
HA
M
D1
7 
15 18.48 N/A 131 
Heun 
2013  
multi 
centr
es 
222 71
.8
4 
N/A 68.96 N/A M
M
SE 
(2
9.1
7) 
HA
M
D1
7 
22 26.77 N/A 22.84 
Hsu 
2016  
US + 
Cana
da 
168 66 14 57 88 M
M
SE 
(N
/A) 
M
AD
RS 
15 28 40 104 
Jorge 
2008 
US 
92 63
.6
7 
13.89 55.43 N/A M
M
SE 
(2
8.1
) 
HA
M
D 
17 
N/
A 
18.57 N/A N/A 
Kaneriy
a 
2016  
US + 
Cana
da 
181 67
.3
6 
14.16 56.91 87.8
7 
M
M
SE 
(N
/A) 
M
AD
RS 
15 23.26 N/A N/A 
Katon 
2010  
US 
871 71 N/A 63.83 78.6
4 
Six 
ite
m 
co
gni
tiv
e 
scr
ee
ne
r 
(N
/A) 
SC
L-
20 
N/
A 
N/A N/A N/A 
Kin 
1997  
multi 
95 69
.6
8 
N/A 70.34 N/A M
M
SE 
HA
M
D1
18 23.5 N/A N/A 
centr
es 
(2
8.6
8) 
7 
Kok 
2009
a 
Nethe
rlands 
82 72
.2
4 
N/A 72.84 N/A M
M
SE 
(2
5.9
3) 
M
AD
RS 
20 32.83 N/A 22.04
†
 
Kok 
2009
b 
Nethe
rlands 
81 72
.2
1 
N/A 72.84 N/A M
M
SE 
(2
5.8
9) 
M
AD
RS 
20 32.9 N/A 21.76
†
 
Koran 
1995  
US 
671 68
.6 
N/A 55 94 M
M
SE 
(2
9) 
HA
M
D 
21 
16 N/A N/A N/A 
Korte 
2012 
Nethe
rlands 
202 63 * 76.7 N/A N/
A 
CE
S-
D 
10 20.5 N/A N/A 
Krahn 
2006  
US 
1531 73
.9 
* 30.7 45.1 Sh
ort 
for
m 
he
alt
h 
inv
en
tor
y 
(3
7.6
) 
CE
S-
D 
N/
A 
24.95 N/A N/A 
Krishna
n 
2001  
US 
220 67
.9
9 
N/A 61.83 N/A M
M
SE 
(2
8.5
4) 
HA
M
D 
24 
18 24.86 N/A N/A 
Laidlaw 
2008  
UK 
40 74 10 72.5 N/A M
M
SE 
(2
8.1
25
) 
HA
M
D2
4 
24 11.6 N/A N/A 
Mavand
adi 
2007 
US 
524 73
.7
7 
N/A N/A N/A N/
A 
CE
S-
D 
N/
A 
23.69 N/A N/A 
Morse 
2005  
US 
160 67
.7 
* 75 92.5 M
M
SE 
(2
9.3
) 
HA
M
D 
17 22.5 47.9 N/A 
Mulsant 
2001 
US 
116 72
.1 
N/A 71.6 86.2 M
M
SE 
(5
6.5
) 
HA
M
D1
7 
15 22.4 60.6 26 
Murphy 
2013 
US 
246 71
.8
5 
N/A 51.62 N/A M
M
SE 
(2
8.7
) 
HA
M
D1
7 
18 22.3 N/A * 
Narushi
ma 
2010 
US 
43 62
.8
5 
14.07 58.05 97.6
6 
M
M
SE 
(2
7.8
2) 
HA
M
D1
7 
14 16.59 N/A N/A 
Navarro 
2001 
Spain 
58 70
.6
9 
N/A 63.8 N/A M
M
SE 
(2
6.6
4) 
HA
M
D 
21 26.76 66.0
7 
6.71 
Rapapor
t 
2003  
US 
319 69
.9
6 
N/A 56.11 95.2
9 
M
M
SE 
(N
/A) 
HA
M
D1
7 
18 22.17 N/A 180.96
†
 
Raskin 
2008 
Cana
da 
311 72
.8
3 
N/A 59.48 78.1
4 
M
M
SE 
(2
2.8
6) 
HA
M
D1
7 
18 18.83 N/A 55.67 
Riebe 
2012 
 US 
906 71 * 56.1 78.3 Six 
ite
m 
co
gni
tiv
SC
L-
20 
N/
A 
* N/A N/A 
e 
scr
ee
ne
r 
(N
/A) 
Roose 
2004  
US 
174 79
.6 
13.8 58.1 N/A M
M
SE 
(2
8) 
HA
M
D2
4 
20 24.3 68.3 12.82 
Rosenth
al 
2005 
US 
34 66 N/A N/A 85 M
M
SE 
(N
/A) 
BD
I 
N/
A 
N/A 36 N/A 
Sallowa
y 
2002  
US 
170 75
.8
8 
N/A sertralin
e 41%, 
citalopra
m 61% 
85 M
M
SE 
(N
/A) 
HA
M
D1
7 
18 23.09 62.7
7 
N/A 
Sarginso
n 
2010
a US 
246 74
.2 
N/A 51.22 91.8
7 
M
M
SE 
(N
/A) 
HA
M
D1
7 
18 22.35 N/A N/A 
Sarginso
n 
2010
b US 
246 74
.2 
N/A 51.22 91.8
7 
M
M
SE 
(N
/A) 
HA
M
D1
7 
18 22.33 N/A N/A 
Schweiz
er 
1998 
US 
177 72 N/A 53 N/A N/
A 
HA
M
D 
17 
18 24.03 60 * 
Singh 
1997  
US 
32 70
.9
4 
14.37 62.5 N/A M
M
SE 
(2
8.5
) 
BD
I 
12 19.94 N/A 118.4
†
 
Smagul
a 
2016  
US 
181 66 14 57 88 N/
A 
M
AD
RS 
15 28 40 104 
Small 
1995  
US 
671 N/
A 
N/A N/A N/A M
M
SE 
(N
/A) 
HA
M
D1
7 
16 N/A N/A N/A 
Sneed 
2007  
US 
174 79 * 58 N/A M
M
SE 
(N
/A) 
HA
M
D2
4 
20 24 68 N/A 
Sneed 
2008  
US 
84 79 N/A 54 N/A M
M
SE 
(2
8.4
2) 
HA
M
D2
4 
N/
A 
24.4 N/A N/A 
Sneed 
2011  
US 
38 66 15.7 63 N/A M
M
SE 
(2
7.5
) 
HA
M
D2
4 
16 24.32 46.5 N/A 
Steffens 
2006  
US 
1684 70
.9 
N/A 66.3 76.7 Six 
ite
m 
co
gni
tiv
e 
scr
ee
ne
r 
(5.
55
) 
SC
L-
20 
N/
A 
1.68 N/A N/A 
Tan 
1994  
UK 
63 80 N/A 66.33 N/A A
M
T 
(N
/A) 
GD
S 
15 16.8 N/A N/A 
van 
Schai
k 
2006 
Nethe
rlands 
143 67
.9
3 
* 69.48 N/A M
M
SE 
(2
6.3
5) 
M
AD
RS 
N/
A 
19.35 * N/A 
Volz 
1995 
Germ
any 
189 68 N/A 75.13 N/A N/
A 
HA
M
D 
N/
A 
26.2 N/A N/A 
Zanetid
ou 
2016 
Italy 
121 75
.1
4 
* 71.11 N/A M
M
SE 
(2
6.8
HA
M
D1
7 
18 20.14 N/A N/A 
7) 
 
Note: N/A = not applicable or not available, * = data in categorical form, 
†
 = data calculated from 
months or years to weeks by multiply by 4 and 52, respectively. 
Cognitive screening tools MMSE = Mini-Mental State Examination, AMT = Abbreviated Mental Test 
Score, 3-MS = The Modified Mini-Mental State 
Depression scales HAMD = Hamilton Depression Rating Scale, MADRS = Montgomery-Asberg 
Depression Scale, CES-D = Center for Epidemiologic Studies Depression Scale , GDS = Geriatric 
Depression Scale, BDI = Beck Depression Inventory, SCL-20 = Hopkins Symptom Checklist 
 
Table 2: Study characteristics 
Study 
year 
Ou
tco
me 
Set
ting 
Diag
nosti
c 
crite
ria 
used 
for 
MD
D 
Treatment 
condition(s) 
Comparator / 
control 
condition(s) 
Type 
of 
statisti
cal 
analysi
s used 
for 
predict
ors S
tu
d
y
 d
u
ra
ti
o
n
 (
in
 w
e
e
k
s)
 
Source RCT 
Acker
man 
1997 
RE
S/
RE
M 
pra
ctic
e 
DSM 
III 
Fluoxetine Placebo Regres
sion 
6 Tollefson et al. 
(1995) 
Acker
man 
2000 
RE
S/
RE
M 
pra
ctic
e 
DSM 
III R 
Fluoxetine Placebo Regres
sion 
6 Tollefson et al. 
(1995) 
Adeo
ye 
2000 
RE
S 
pra
ctic
e 
DSM 
III R 
Bupropion 150mg Bupropion 75 
mg 
Bivaria
te 
3
-
1
1 
Primary 
Alexo
poulo
s 
2005 
RE
M 
pra
ctic
e 
DSM 
IV 
Care management Usual care Regres
sion 
7
2
†
 
Bruce et al. 
(2004) 
Alexo
poulo
s 
2014 
SC
OR
E 
pra
ctic
e 
DSM 
IV 
Personalised 
Intervention for 
depression and COPD 
Usual care Regres
sion 
5
2
†
 
Primary 
Alpert 
2003 
SC
OR
E 
mix
ed 
DSM 
III R 
Sertraline Nortriptyline Regres
sion 
1
2 
Bondareff et al. 
(2000) 
Andre
escu 
RE
S 
pra
ctic
DSM 
IV 
Pharmacotherapy +  
Clinical management / 
Placebo Surviva
l 
1
2
Reynolds et al. 
(2006) 
2007 e Placebo +  
Clinical management / 
Pharmacotherapy  + 
IPT / Placebo + IPT 
analysi
s 
0 
Andre
escu 
2009 
RE
S 
pra
ctic
e 
DSM 
IV 
Pharmacotherapy +  
Clinical management / 
Placebo +  
Clinical management / 
Pharmacotherapy  + 
IPT / Placebo + IPT 
Placebo Bivaria
te 
1
0
4
†
 
Reynolds et al. 
(2006) 
Azar 
2011 
RE
M 
pra
ctic
e 
DSM 
IV 
Integrated care model Enhance 
specialty 
referral 
model 
Regres
sion 
2
4
†
 
Krahn et al. 
(2006a) 
Baner
jee 
1996 
SC
OR
E 
pra
ctic
e 
AGE
CAT 
Psychogeriatric team Usual care Regres
sion 
2
4
†
 
Primary 
Bao 
2011 
SC
OR
E 
pra
ctic
e 
DSM 
IV 
Care management Usual care Regres
sion 
9
6
†
 
Bruce et al. 
(2004) 
Beaud
reau 
2015 
RE
S/
RE
M 
pra
ctic
e 
DSM 
IV 
Problem solving 
therapy 
Supportive 
therapy 
ROC 
analysi
s 
1
2 
Arean et al. 
(2010) 
Bjolse
th 
2015 
RE
M 
pra
ctic
e 
DSM 
IV TR 
ECT bifrontal  ECT right 
unilateral 
Regres
sion 
1
2 
Primary 
Bogne
r 
2007 
RE
S/
RE
M 
pra
ctic
e 
DSM 
IV 
Care management Usual care Regres
sion 
1
6 
Bruce et al. 
(2004) 
Bogne
r 
2012 
CA
T 
pra
ctic
e 
DSM 
IV 
Care management Usual care Regres
sion 
9
6
†
 
Bruce et al. 
(2004) 
Bond
areff 
2000 
SC
OR
E 
co
mm
unit
y 
DSM 
III R 
Sertraline Nortriptyline Surviva
l 
analysi
s 
1
2 
Primary 
Cappe
liez 
2007 
RE
M 
pra
ctic
e 
DSM 
IV 
8 weeks treatment 
plan + problem solving 
intervention (optional) 
Usual care Bivaria
te 
8 Primary 
Chan 
2013 
SC
OR
E 
co
mm
unit
y 
N/A Life story book 
creation 
Visit Regres
sion 
8 Primary 
Chan 
2014 
SC
OR
E 
co
mm
unit
y 
N/A Life story review Visit Regres
sion 
8 Primary 
Coon 
2003 
SC
OR
pra
ctic
RDC CBT + Desipramine CBT alone Regres
sion 
1
6
Thompson et al. 
(2001) 
E e 
†
 
Evans 
1997 
RE
S 
pra
ctic
e 
GMS
/ 
AGE
CAT 
Fluoxetine Placebo Regres
sion 
8 Evans et al. 
(1997a) 
Eyre 
2016 
RE
M 
pra
ctic
e 
DSM 
IV 
Methylphenidate + 
Citalopram 
Methylpheni
date / 
Citalopram 
Bivaria
te 
1
6 
Lavretsky et al. 
(2015) 
Fields 
2012 
SC
OR
E 
pra
ctic
e 
not 
speci
fied 
Celecoxib/  
Naproxen sodium 
Placebo Regres
sion 
2
6
0
†
 
Lyketsos et al. 
(2007) 
Gasto 
2003 
RE
M 
pra
ctic
e 
DSM 
IV 
Venlafaxine Nortriptyline Bivaria
te 
2
4 
Primary 
Ghesq
uiere 
2014 
RE
M 
pra
ctic
e 
DSM 
IV 
Care management Usual care Regres
sion 
1
6
†
 
Bruce et al. 
(2004) 
Gilde
ngers 
2002 
RE
S 
pra
ctic
e 
DSM 
IV 
Paroxetine Nortriptyline Regres
sion 
1
2 
Reynolds et al. 
(1999) 
Gilma
n 
2013 
SC
OR
E 
pra
ctic
e 
DSM 
IV 
Care management Usual care Regres
sion 
1
0
4
†
 
Bruce et al. 
(2004) 
Green
lee 
2010 
RE
M 
pra
ctic
e 
DSM 
IV 
IPT +  
Care management 
Care 
management 
Surviva
l 
analysi
s 
1
6 
Reynolds et al. 
(2010) 
Heun 
2013 
RE
S 
pra
ctic
e 
DSM 
IV TR 
Agomelatine Placebo Regres
sion 
8 Primary 
Hsu 
2016 
RE
M 
pra
ctic
e 
DSM 
IV 
Venlafaxine + 
Aripiprazole 
Venlafaxine Bivaria
te 
1
2 
Lenze et al. 
(2015) 
Jorge 
2008 
SC
OR
E 
pra
ctic
e 
DSM 
IV 
rTMS Sham Regres
sion 
1
.
5
†
 
Primary 
Kaner
iya 
2016 
RE
M 
pra
ctic
e 
DSM 
IV 
Venlafaxine + 
Aripiprazole 
Venlafaxine Regres
sion 
1
2 
Lenze et al. 
(2015) 
Katon 
2010 
RE
M 
pra
ctic
e 
DSM 
IV 
Care management + 
activities + Problem 
Solving in Primary Care 
Usual care Regres
sion 
9
6
†
 
Unutzer et al. 
(2002) 
Kin 
1997 
RE
S 
pra
ctic
e 
DSM 
III 
Moclobemide Nortriptyline 
/ Placebo 
Bivaria
te 
7 Nair et al. 
(1995) 
Kok 
2009a 
RE
M 
pra
ctic
e 
DSM 
IV 
Venlafaxine Nortriptyline Surviva
l 
analysi
1
2 
Kok et al. (2007) 
s 
Kok 
2009b 
RE
M 
pra
ctic
e 
DSM 
IV 
Venlafaxine Nortriptyline ROC 
analysi
s 
1
2 
Kok et al. (2007) 
Koran 
1995 
RE
S/
RE
M 
pra
ctic
e 
DSM 
III R 
Fluoxetine Placebo Regres
sion 
6 Primary 
Korte 
2012 
SC
OR
E 
pra
ctic
e 
MINI Life review therapy Usual care Regres
sion 
3
6 
Korte et al. 
(2009) 
Krahn 
2006 
SC
OR
E 
pra
ctic
e 
MINI Integrated care Enhanced 
specialty 
referral 
Regres
sion 
2
4 
Levkoff et al. 
(2004)  
Krishn
an 
2001 
RE
S 
pra
ctic
e 
DSM 
III R 
Sertraline/Nortriptylin
e 
Placebo Regres
sion 
1
2 
Bondareff et al. 
(2000), 
Newhouse et al. 
(2000)  
Laidla
w 
2008 
SC
OR
E 
pra
ctic
e 
DSM 
IV 
CBT Usual care ANCO
VA 
2
4
†
 
Primary 
Mava
ndadi 
2007 
SC
OR
E 
pra
ctic
e 
DSM 
IV 
Integrated care Specialty 
referral care 
Regres
sion 
5
2
†
 
Krahn et al. 
(2006a) 
Mors
e 
2005 
RE
S 
pra
ctic
e 
SAD
S 
Nortriptyline+ IPT Placebo Surviva
l 
analysi
s 
2
6 
Reynolds et al. 
(1999) 
Mulsa
nt 
2001 
RE
S 
pra
ctic
e 
DSM 
IV 
Nortriptyline Paroxetine Regres
sion 
1
2 
Mulsant et al. 
(1999) 
Murp
hy 
2013 
SC
OR
E 
pra
ctic
e 
DSM 
IV 
Mirtazapine Paroxetine Princip
al 
compo
nent 
8 Schatzberg et al. 
(2002) 
Narus
hima 
2010 
RE
S 
mix
ed 
DSM 
IV TR 
rTMS Placebo Regres
sion 
2 Primary 
Navar
ro 
2001 
RE
M 
pra
ctic
e 
DSM 
IV 
Citalopram Nortriptyline Bivaria
te 
1
2 
Primary 
Rapap
ort 
2003 
SC
OR
E 
pra
ctic
e 
DSM 
IV 
Paroxetine CR/ 
Paroxetine IR 
Placebo Regres
sion 
1
2 
Primary 
Raski
n 
2008 
RE
S 
pra
ctic
e 
DSM 
IV 
Duloxetine Placebo Surviva
l 
analysi
s 
8 Raskin et al. 
(2007) 
Riebe 
2012 
RE
S 
pra
ctic
e 
DSM 
IV 
Care management + 
Activities + Problem 
Solving in Primary Care 
Usual care Regres
sion 
5
2
†
 
Unutzer et al. 
(2002) 
Roose 
2004 
RE
S/
RE
M 
mix
ed 
DSM 
IV 
Citalopram Placebo Regres
sion 
8 Primary 
Rosen
thal 
2005 
SC
OR
E 
pra
ctic
e 
DSM 
III R 
Antidepressants+ 
Clinical management+ 
Dialectical behaviour 
therapy 
Antidepressa
nts + Clinical 
management 
Regres
sion 
2
8 
Lynch et al. 
(2003) 
Sallo
way 
2002 
SC
OR
E 
pra
ctic
e 
DSM 
IV 
Sertraline (old) / 
Citalopram (very old) 
Placebo Bivaria
te 
8 Schneider et al. 
(2003) 
Sargin
son 
2010a 
RE
S 
pra
ctic
e 
DSM 
IV 
Mirtazapine Paroxetine Regres
sion 
8 Murphy et al. 
(2003), 
Schatzgerg et al. 
(2002)  
Sargin
son 
2010b 
RE
M 
pra
ctic
e 
DSM 
IV 
Mirtazapine Paroxetine Regres
sion 
8 Murphy et al. 
(2003), 
Schatzgerg et al. 
(2002)  
Schw
eizer 
1998 
SC
OR
E 
pra
ctic
e 
DSM 
III R 
Buspirone / 
Imipramine 
Placebo Factori
al 
analysi
s 
8 Primary 
Singh 
1997 
SC
OR
E 
co
mm
unit
y 
DSM 
IV 
High intensity 
progressive resistance 
training 
Interactive 
health 
education 
program 
Regres
sion 
1
0 
Primary 
Smag
ula 
2016 
SC
OR
E 
pra
ctic
e 
DSM 
IV 
Venlafaxine + 
Aripiprazole 
Venlafaxine + 
Placebo 
Bivaria
te 
1
2 
Lenze et al. 
(2015) 
Small 
1995 
SC
OR
E 
pra
ctic
e 
DSM 
III R 
Fluoxetine Placebo Regres
sion 
6 Tollefson et al. 
(1995) 
Sneed 
2007 
SC
OR
E 
co
mm
unit
y 
DSM 
IV 
Citalopram Placebo Regres
sion 
8 Roose et al. 
(2004a) 
Sneed 
2008 
RE
S 
pra
ctic
e 
DSM 
IV 
Citalopram Placebo Regres
sion 
8 Roose et al. 
(2004a) 
Sneed 
2011 
RE
M 
mix
ed 
DSM 
IV 
Sertraline Nortriptyline Regres
sion 
1
2 
Primary 
Steffe
ns 
2006 
SC
OR
E 
pra
ctic
e 
DSM 
IV 
Care management + 
Activities + Problem 
Solving in Primary Care 
Usual care Regres
sion 
9
6
†
 
Unutzer et al. 
(2002) 
Tan 
1994 
SC
OR
E 
pra
ctic
e 
N/A Iofepramine Placebo Bivaria
te 
5 Primary 
van 
Schaik 
2006 
RE
S 
pra
ctic
e 
PRI
ME-
MD 
IPT Usual care Regres
sion 
2
4 
Primary 
Volz 
1995 
CA
T 
pra
ctic
e 
DSM 
III 
Brofaromine Imipramine Bivaria
te 
8 Moller and Volz 
(1992,1993)  
Zaneti
dou 
2016 
RE
M 
pra
ctic
e 
DSM 
IV 
Sertraline +  
Physical exercise 
Sertraline Regres
sion 
2
4
†
 
Belvederi M. et 
al. (2015) 
 
Note:  
Outcome RES = response, REM = remission, SCORE = score on depression questionnaire, CAT = 
depression categories (e.g. high persistent, high decline and low decline) 
Diagnostic criteria DSM = Diagnostic and Statistical Manual of Mental Disorders, PRIME-MD = 
Primary Care Evaluation of Mental Disorders screening questionaire for depressive symptoms, MINI 
= The M.I.N.I. International Neuropsychiatric Interview, SADS= Schedule for Affective Disorders and 
Schizophrenia-Lifetime Version, GMS/AGECAT = Geriatric Mental Scale/AGECAT 
Intervention CBT = Cognitive behavioural therapy, IPT = Interpersonal psychotherapy, ECT= 
Electroconvulsive therapy, rTMS = repetitive Transcranial Magnetic Stimulation 
†
 = data calculated from months or years to weeks by multiply by 4 and 52, respectively. 
 
Table 3: Statistically significant predictors of response, remission and depression score or 
category 
Factors Predictors  Response  Remission  Score/Category 
Demographic     
Ethnic Black +  Ackerman 
1997a 
Ackerman 
2000a 
    
 White     + Bao 2011c  
Smagula 2016a 
Age Older age   + Zanetidou 
2016d 
+ Bogner 2012c 
  - Jorge 
2008d 
- Riebe 2012c - Bondareff 
2000a  
Chan 2013b 
Gender Female - Raskin 
2008a 
- Raskin 
2008a 
  
Marital status Being married + Bogner 
2012c 
  - Lailaw 2008b 
Education Higher level     + Gilman 2013c 
      - Bao 2011c 
Socioeconomic Financial strain     - Gilman 2013c 
 Social support     + Gilman 2013c 
        
Clinical        
Depression Baseline severity + Roose 
2004a 
van Schaik 
2006b 
  + Tan 1994a 
  -  Mulsant 
2001a  
- Ackerman 
1997a 
Alexopoulos 
2005c 
Azar 2011c  
Bjolseth 
2015d 
Capaeliez 
2007c 
Ghesquier 
2014c Katon 
2010c  
Kok 2009aa 
Raskin 
2008a 
- Banerjee 1996c 
Coon 2007b  
Mavandadi 
2007c  
Rosenthal 
2005b 
 
 Early improvement + Koran 
1995a 
Kok 
2009ba 
+ Koran 1995a + Volz 1995a 
 Current episode 
duration 
- Mulsant 
2001a 
- Kok 2009aa - Rapaport 2003a 
 Severe group 
(endogenous, 
psychotic,  severe 
inhibition) 
  + Navarro 
2001a 
  
 Age of initial onset     + Rosenthal 
2005b 
 First episode     - Banerjee 1996c 
 Previous 
antidepressant 
failure 
  - Hsu 2016a   
Anxiety Baseline severity - Ackerman 
2000a 
Andreescu 
2007abc  
- Ackerman 
1997a 
Alexopoulos 
2005c  
Azar 2011c  
Kaneriya 
2016a 
Zanetidou 
2016d 
  
 Severity at 6 week of 
treatment 
  - Greenlee 
2010b 
  
 Worry and panic - Andreescu 
2009abc 
    
Other symptoms Psychotic - Bjolseth 
2015d 
+ Bjolseth 
2015d 
  
 Suicidal ideation     - Bogner 2012c 
 Psychomotor 
retardation 
  + Zanetidou 
2016d 
  
 Somnolence + Ackerman 
2000a 
    
 Somatisation - Ackerman 
1997a 
    
 Somatic symptoms   - Cappeliez 
2007c 
  
 Hopelessness   - Alexopoulos 
2005c 
  
 Limitation of 
emotional function 
  - Alexopoulos 
2005c 
  
 Perceived adequacy 
of emotional and 
+ Cappeliez     
instrumental support 2007c 
 Engagement in 
pleasant activity 
  + Riebe 2012c   
Personality Cluster C personality 
disorder 
- Morse 
2005abc 
    
 Extraversion trait     + Korte 2012b 
        
Physical Physical illness -  Evans 
1997a 
- Alexopoulos 
2005c 
Azar 2011c 
- Bogner 2012c 
Chan 2014b  
Gilman 2013c 
Krahn 2006c 
 Pain   - Raskin 
2008a 
- Mavandadi 
2007c 
 Cerebrovascular 
disease 
- Evans 
1997a  
Raskin 
2008a 
    
 Polypharmacy   + Zanetidou 
2016d 
  
 Headache + Ackerman 
2000a 
    
        
 Limitation of physical 
function 
  - Alexopoulos 
2005c 
  
 Dyspnea-related 
disability 
    - Alexopoulos 
2014c 
 Maximum Oxygen 
uptake (VO2max) 
  + Zanetidou 
2016d 
  
Investigation        
Blood Bupropion plasma 
concentration 
+ Adeoye 
2000 a 
    
 Erythrobupropion 
and threobupropion 
- Adeoye 
2000 a 
    
 Folic level     + Alpert 2003 a 
 Cortisol level - Kin 1997a     
 Dexamethasone 
suppression test: 
suppressor 
+ Kin 1997 a     
EEG Low-theta power in 
subgenual ACC 
cluster 
+ Narushima 
2010d 
    
Genetic 
rs1360780 
-  Sarginson 
2012b a 
    
 
rs3800373 
-  Sarginson 
2012b a 
    
 
rs2032583 C carrier 
  +  Sarginson 
2012a a 
  
 
rs2235040 A carrier 
  +  Sarginson 
2012a a 
  
 BDNF variant     ? Murphy 2013 a 
 CREB1 variant     ? Murphy 2013 a 
 HLA-DRB5   ? Eyre 2016 a   
 SELENBP1   ? Eyre 2016 a   
 LOC388588   ? Eyre 2016 a   
Neuropsychological        
General cognition  
MMSE >23 
+ Evans 
1997 a 
    
 Cognitive decline     - Steffens 2006c 
 Attention     + Smagula 2016 a 
 Immediate memory     + Smagula 2016 a 
Executive function Response inhibition 
in Stroop 
- Bogner 
2007c 
- Bogner 
2007c 
- Sneed 2007 a 
 Trail Making Test :set 
shifting 
+ Beaudreau 
2015b 
+ Kaneriya 
2016 a 
+ Smagula 2016 a 
        
Brain imaging        
 Deep white matter 
hyperintensity 
- Sneed 
2011 a 
    
 Periventricular 
hyperintensity 
- Sneed 
2011 a 
    
 Total hyperintensity 
volume 
- Sneed 
2011 a 
    
 Gray matter volume 
in left and  
right frontal brain 
region 
  + Jorge 2008d   
Note: + = positive prediction to outcome, - = negative prediction to outcome, ? = direction of 
prediction to outcome was not identified. 
Subscript: a= pharmacologic study, b=psychological therapy study, c= care management study, d= 
rTMS or ECT study, abc= combined pharmacotherapy, psychological and care management study. 
 
 
Table 4: Results of meta-analysis for each predictor variable of good outcome. 
Predic
tor 
St
udy 
Pool
ed 
OR 
95% CI z p Q p 
I
2 
(%
) 
Tau
2
 
Egger 
bias 
estim
ate 
95% CI p 
Age 6 0.78
3 
0.4
57 
1.3
42 
-
0.8
88 
0.37
4 
24.
31 
<.0
01 
79
.4 
0.31
02 
-
0.633 
-
3.6
68 
2.40
3 
0.59
4 
Baseli
ne 
anxiet
y 
7 0.44
7 
0.2
71 
0.7
36 
-
3.1
63 
0.00
2 
32.
70 
<.0
01 
81
.7 
0.27
52 
2.467 -
3.0
93 
-
1.84
1 
<0.0
01 
Baseline 
depression
14 0.88
6 
0.8
33 
0.9
43 
-
3.8
28 
<0.0
01 
75.
97 
<.0
01 
82
.9 
0.00
53 
-
1.648 
-
3.1
11 
-
0.18
5 
0.03
0 
Trail 
makin
g test 
3 2.24
7 
1.4
05 
3.5
93 
3.3
81 
0.00
1 
1.2
3 
0.5
40 
0.
0 
0.00
00 
0.944 -
9.7
59 
11.6
47 
0.46
4 
Physic
al 
illness 
5 0.84
3 
0.7
12 
0.9
98 
-
1.9
80 
0.04
8 
35.
62 
<.0
01 
88
.8 
0.02
08 
-
2.950 
-
5.7
77 
-
0.12
3 
0.04
5 
 
  
 
Table 5: Results of subgroup meta-analyses by treatment type for each predictor. 
Predictor 
 Treatment type 
No. 
of 
study 
Pooled OR 
(95% CI) 
Overall 
effect: z (p 
value) 
I
2
 % (p 
value) 
Publication 
bias: Egger 
bias 
estimate 
(p value) 
Subgroup 
differences†: 
I
2
 (p value) 
Age      82.9 (0.003) 
 Biological 3 0.447 
(0.221, 
0.903) 
2.24(0.025) 59.3 
(0.086) 
-0.355 
(0.976) 
 
 Psychosocial 1 0.973 
(0.457, 
1.342) 
0.04 
(0.970) 
87.0 
(0.006) 
N/A  
 Biological plus 
psychosocial 
2 1.428 
(0.593, 
3.440) 
0.79 
(0.427) 
N/A UC  
       
Baseline depression      86.0 (0.001) 
 Biological 5 0.786 
(0.575, 
1.075) 
1.51 
(0.132) 
85.1 
(<0.001) 
-0.719 
(0.709) 
 
 Psychosocial 2 0.472 
(0.187, 
1.192) 
1.59 
(0.112) 
49.5 
(0.159) 
UC  
 Biological plus 
psychosocial 
7 0.922 
(0.874, 
0.973) 
2.98 
(0.003) 
81.8 
(<0.001) 
-2.182 
(0.065) 
 
       
Baseline anxiety      94.5 
(<0.001) 
 Biological 4 0.273 
(0.154, 
0.484) 
4.44 
(<0.001) 
0 
(0.752) 
-1.346 
(0.311) 
 
 Psychosocial 0 N/A N/A N/A N/A  
 Biological plus 
psychosocial 
3 0.656 
(0.399, 
1.079) 
1.66 
(0.097) 
85.1 
(0.001) 
-2.941 
(0.052) 
 
       
Physical illness      95.5 
(<0.001) 
 Biological 0 N/A N/A N/A N/A  
 Psychosocial 1 0.016 
(0.003, 
0.089) 
4.76 
(<0.001) 
N/A N/A  
 Biological plus 4 0.900 1.91 77.6 -2.147  
psychosocial (0.808, 
1.002) 
(0.056) (0.004) (0.115) 
       
Executive functioning 
(Trail Making Test) 
     18.0 (0.269) 
 Biological 2 2.080 
(1.276, 
3.391) 
2.94 
(0.003) 
0 
(0.930) 
UC  
 Psychosocial 1 5.571 
(1.042, 
29.790) 
2.01 
(0.045) 
N/A UC  
 Biological plus 
psychosocial 
0 N/A N/A N/A N/A  
       
 
Note:   Biological treatment type consisted of data from pharmacological trials and 
rTMS/ECT trials. 
  Psychosocial treatment type consisted of data from psychological treatment 
trials.  
  Biological plus psychosocial treatment type consisted of data from care 
management and combined treatment trials. 
 † Overall test for heterogeneity between subgroup. Bonferroni-corrected alpha 
level of 0.01, adjusted for the number of treatment type subgroup analyses. 
 N/A is for not available. UC is for unable to calculate. 
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Highlights  
· Older age and executive functioning impairment predicted poor outcome.  
· Presence of co-morbid anxiety and physical illnesses also predicted poor outcome. 
· Lower baseline depression severity, shorter episode duration and early improvement 
predicted good outcome. 
· Meta-analysis confirmed baseline depression, anxiety and TMT associated with outcome. 
· Subgroup analyses revealed treatment specific predictor, but with limitation. 
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